Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QGLY - Funny Name Great Product. -- Ignore unavailable to you. Want to Upgrade?

To: VIPER85730 who wrote (8889)	5/31/1999 10:55:00 AM
From: Ironyman	Read Replies (1) \| Respond to of 8960

Has anyone mentioned to Guy that most diabetiic related products fair rather poorly. That market is SUPERSATURATED!!!! Examples-- BIME & BICO. There might be a real juicy short coming down the line. Regards, Burned by QGLY!

To: VIPER85730 who wrote (8889)	6/14/1999 12:14:00 AM
From: George Eby	Respond to of 8960

Look at a package. It lists palm kernel oil. When boiled together zinc acetate and palm kernel oil form zinc palmitate -- a wax -- totally insoluble in water and non ionizable (a violation of the agreement), and not absorbed by the body. This is a problem that is typical of what inventors face -- the idea that the inventor has an idea, but needs improving. Weird, that they did not read the first paragraph or two in every one of my patents about the problem of zinc ions spoiling certain fats. No, Quigley had nothing to do with it at all. Believe me, the zinc palmitate product will not be on the shelf this fall, although some leftovers may be out there. However, Chuck Phillips of Quigley Corp. did modify the original Cold-Eeze formula to everyone's benefit. The original - Godfrey - design turned brown with time through a chemical reaction involving free glycine and sugars. The Cold-Eeze product that took its place for the Cleveland clinic study, I believe is vastly superior to the original Godfrey design. Look at the Godfrey lozenges at coldcure.com. The current Cold Eeze contains no free glycine. It is all bound by zinc to form positively charged and effective zinc glycinate+1 ionic species and probably some zinc gluconate+1 ionic species.

To: VIPER85730 who wrote (8889)	7/21/1999 12:00:00 PM
From: James M. Bash	Read Replies (1) \| Respond to of 8960

From: Analyst Forum Pharmaceutical stocks good for the long haul cbs.marketwatch.com And if you want to go for some of the strong ones that are really interesting that are not for Grandma, not for the weak of heart, if you take a look at a company like Quigley (QGLY: news, msgs) -- it sells Cold-Eeze, the cough/cold zinc lozenge. The company's accumulated about $125 million in sales over the last couple years. They have a zinc lozenge ... which is proven to reduce the average duration of the common cold by 42 percent ... basically a three-day reduction. It's a stock that hasn't been covered by Wall Street, yet they've got a product out in the marketplace. It's the number two cough/cold lozenge in the marketplace. It's a top 10 cold product overall. There's a lot of interesting stories out there, some like Quigley, some like [... another company mentioned ...] These companies are microcapitilization companies and because of today's current environment focused on large caps, they're largely being overlooked. But they're certainly worthy of taking a look at what they have to offer, especially since those companies all have revenues and they all have real products on the market. Nice to see QGLY moving up again. Sorry for all those who sold at the low...